Trial Profile
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 09 Apr 2021 Planned End Date changed from 14 Dec 2023 to 31 Mar 2024.
- 17 Jan 2021 Primary endpoint (Overall Response Rate) has been met as per results presented at the 2021 Gastrointestinal Cancers Symposium.
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium